Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Vir Biotechnology's EBITDA for the
three
months ended in Jun. 2026 was $76.3 Mil. Vir Biotechnology's Revenue for the
three
months ended in Jun. 2026 was $238.9 Mil. Therefore, Vir Biotechnology's EBITDA margin for the quarter that ended in Jun. 2026 was 31.92%.
Vir Biotechnology (NAS:VIR) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Vir Biotechnology EBITDA Margin % Related Terms
Vir Biotechnology EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Vir Biotechnology's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VIR vs AVBP, XNCR, SEPN: EBITDA Margin % Comparison
For the Biotechnology subindustry, Vir Biotechnology's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vir Biotechnology EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vir Biotechnology's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Vir Biotechnology's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vir Biotechnology (VIR) has a EBITDA Margin % of 31.92% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vir Biotechnology and its competitors. According to the industry distribution chart, Vir Biotechnology ranks #502 out of 942 companies in the Biotechnology industry, placing it in the top 53.3%.
Is Vir Biotechnology's EBITDA Margin % too high?
Vir Biotechnology's current EBITDA Margin % is 31.92%. Based on the distribution chart, Vir Biotechnology ranks #502 out of 942 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vir Biotechnology has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vir Biotechnology's EBITDA Margin % compare to AVBP and XNCR?
According to the Biotechnology industry distribution chart, Vir Biotechnology ranks #502 out of 942 companies for EBITDA Margin %. This places Vir Biotechnology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vir Biotechnology and its competitors. Vir Biotechnology's current EBITDA Margin % is 31.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vir Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Vir Biotechnology (VIR) is currently considered Possible Value Trap. The stock's GF Value™ is $42.26, compared to a current price of $9.50 — trading 77.5% below its estimated fair value. The current EBITDA Margin % is 31.92%. Vir Biotechnology's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Vir Biotechnology (VIR), the current EBITDA Margin % is 31.92% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vir Biotechnology (VIR) Overvalued in 2026?
Based on GuruFocus' analysis, Vir Biotechnology stock appears to be undervalued.
The current stock price of $9.50 is trading 77.5% below its estimated GF Value™ of $42.26.
GuruFocus considers Vir Biotechnology to be Possible Value Trap.
Key valuation signals for VIR:
EBITDA Margin %: 31.92%
GF Value™: $42.26 vs. price of $9.50 (77.5% below fair value)
No single metric tells the full story. See the VIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
52GF Score
Get the complete analysis for VIR
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VIR has been successfully added to your 
